The Trump administration rolled out its new TrumpRx prescription drug listing site late Thursday, delivering on a months-long push by President Trump to slash direct-to-consumer drug prices. The site lists dozens of prescription drugs at reduced rates, backed by deals the administration struck last year with more than a dozen pharmaceutical companies — including Pfizer and Novo Nordisk — to offer steep discounts from list prices.
President Trump didn't mince words at the White House event Thursday evening:
"One of the most transformative health care initiatives of all time."
The mechanics are simple. Gold-embossed coupons. Discounted prices. No insurance middlemen. Americans who have spent years watching drug costs climb while Washington held hearings and issued press releases now have a searchable site with real numbers attached to real medications.
As reported by CBS News, a four-week supply of Wegovy injection pens — the weight-loss drug reshaping American medicine — is listed at $199 for the first two months and $349 after that. The list price sits at $1,349.02. That's not coupon-clipping savings. That's a demolition.
A unit of Gonal-F, the IVF drug, lands at $252 on TrumpRx — an 83% discount from the sticker price. For families navigating the brutal economics of fertility treatment, that number changes the calculus overnight. Trump pledged on the campaign trail to ensure that fertility treatments are fully covered either by private insurance or the government. The Gonal-F listing is a tangible down payment on that promise.
Trump connected the initiative to a problem every American who has ever filled a prescription understands:
"Americans have long been paying the highest drug prices anywhere in the world while other countries often paid pennies on the dollar for the exact same drugs. We were essentially subsidizing the entire world."
That's not campaign rhetoric anymore. It's the thesis behind an operational website.
The consumer-facing site is the visible storefront. The structural reform runs deeper. Several pharmaceutical companies agreed to offer drugs to Medicaid patients at most-favored-nation prices, meaning they cannot charge more than the prices paid by people in other high-income countries. Companies also agreed to extend most-favored-nation pricing for new drugs introduced in the U.S. market.
That second commitment deserves attention. Without it, the pharmaceutical industry could simply front-load prices on new therapies to recoup what they surrender on existing ones. The deal forecloses that escape hatch. New drugs enter the American market at the same price that the rest of the developed world pays.
For years, lawmakers proposed capping U.S. drug prices. None delivered. Trump went directly to the manufacturers and forced the issue through negotiation, not legislation. Congressional price caps require 60 votes in the Senate and survive approximately zero lobbying cycles. Executive-branch deals with willing companies require a president willing to use leverage. Trump used it.
TrumpRx is not a government pharmacy. It's not a new entitlement. The site itself carries a telling note:
"If you have insurance, check your co-pay first—it may be even lower."
That's an unusual posture for any administration launching a signature initiative — openly acknowledging that some consumers might find a better deal elsewhere. It signals confidence, not desperation.
Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, put it in practical terms Thursday:
"You should not be buying drugs anymore, going forward, without at least checking to see if those medications are available at these discounted prices."
Joe Gebbia, the administration's Chief Design Officer and an Airbnb founder who helped design the site, said more drugs will be added to TrumpRx over time. The initial offering is a beachhead.
The launch arrives against a backdrop that sharpens its significance. According to drug pricing research nonprofit 46brooklyn, manufacturers raised list prices on 947 brand-name drugs this January. They lowered prices on 20. List prices for brand-name drugs increased by a median of 4% so far in 2026, on par with last year's increase.
The Consumer Price Index for prescription drugs rose 2% between December 2024 and December 2025. Since Trump's second inauguration in January 2025, the CPI for prescription drugs has declined by less than 1%. Modest — but a decline is a decline, and the pharmaceutical industry spent decades building a pricing architecture designed to resist exactly this kind of pressure.
There are genuine bright spots. The list price of Eliquis, a widely used blood thinner, plunged 43%. Jardiance, used to treat Type 2 diabetes, fell 44%. Those are the kinds of price movements that change household budgets — the difference between rationing pills and taking them as prescribed.
Sean Sullivan, a health economist at the University of Washington, told CBS News last year:
"The direct-to-patient stuff is, in my view, a sideshow and branding opportunity for Trump."
He elaborated:
"Most patients have drug coverage. ... Very few are going to buy medications with cash, unless the drug is not a covered benefit, like weight loss or erectile dysfunction drugs."
Read that again. Sullivan's own caveat names the exact categories where TrumpRx delivers its most dramatic savings — weight-loss drugs, fertility medications, and treatments that insurers routinely refuse to cover. Dismissing those categories as niche afterthoughts isn't analysis. It's an attempt to define the site's target population out of relevance while accidentally confirming its value proposition.
The broader point Sullivan sidesteps: the most-favored-nation pricing deals aren't limited to the consumer site. They restructure what pharmaceutical companies can charge Medicaid — affecting millions of the most economically vulnerable patients in the system. TrumpRx is the storefront. The real leverage operates behind the counter.
The 947-to-20 ratio of January price hikes to price cuts tells you the pharmaceutical industry hasn't surrendered. It has conceded ground on specific drugs while continuing to raise prices across the broader portfolio. That tension will define the next phase. The administration holds leverage — Medicaid access, the bully pulpit, and the political appeal of visible price reductions heading into a midterm cycle. Pharma holds patience, lobbyists, and the staggering complexity of the American health system as a shield.
Novo Nordisk had already offered Wegovy for similarly discounted prices through its NovoCare Pharmacy program in recent weeks. The industry was moving toward direct-to-consumer pricing before TrumpRx existed. What the administration did was centralize those deals, brand them, and attach presidential accountability to the outcome.
The families filling those Wegovy prescriptions at $199 instead of $1,349 don't care about the policy architecture. They care that the number on the receipt changed. For a generation of Americans who watched drug prices climb while Washington offered nothing but hearings and hand-wringing, TrumpRx is something unfamiliar.
It's a receipt.